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Abstract. The identification of new contaminants is critical in the development of new medicinal products.
Many impurities, such as pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid,
decanedioic acid, undecanedioic acid, dodecanedioic acid, tridecanedioic acid, and tetradecanedioic acid,
have been identified in samples of azelaic acid. The aim of this study was to identify impurities observed
during the stability tests of a new liposomal dosage form of azelaic acid that is composed of phosphati-
dylcholine and a mixture of ethyl alcohol and water, using high-performance liquid chromatography with
evaporative light-scattering detector (HPLC-ELSD), gas chromatography–flame ionisation detection
(GC-FID), and gas chromatography–mass spectrometry (GC-MS) methods. During the research and
development of a new liposomal formulation of azelaic acid, we developed a method for determining
the contamination of azelaic acid using HPLC-ELSD. During our analytical tests, we identified a previ-
ously unknown impurity of a liposomal preparation of azelaic acid that appeared in the liposomal
formulation of azelaic acid during preliminary stability studies. The procedure led to the conclusion that
the impurity was caused by the reaction of azelaic acid with one of the excipients that was applied in the
product. The impurity was finally identified as an ethyl monoester of azelaic acid. The identification
procedure of this compound was carried out in a series of experiments comparing the chromatograms that
were obtained via the following chromatographic methods: HPLC-ELSD, GC-FID, and GC-MS. The
final identification of the compound was carried out by GC with MS.
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INTRODUCTION
Azelaic acid is a relatively new therapeutic substance that
is used in the treatment of acne. Therapeutic treatment with
15% azelaic acid in a cream formulation has existed for two
decades. Azelaic acid has several pharmacological effects:
antibacterial, keratolytic, bleaching and metabolic (1). Its an-
tibacterial activity is based primarily on its biocidal activity
against Propioniobacterium acnes and Staphylococcus
epidermidis. The drug also reduces the synthesis of keratin,
leading to the suppression of comedogenic activity. Given its
ability to inhibit the synthesis of melanin by inhibiting tyrosi-
nase, azelaic acid is beneficial in the removal of melanin stains
on the skin surface. Its inhibitory effect on 5-alpha-reductase
reduces the formation of dihydrotestosterone that is normally
synthesised in the skin from testosterone. Consequently, re-
duced lipogenesis in the affected tissue is observed (2,3). To
achieve an optimal therapeutic effect, several attempts have
been made to modify the formulations of anti-acne drugs,
including binding with ionic polymers (4) or evaluating the
liposomal formulations (5).
Many impurities, such as pentanedioic acid, hexanedioic
acid, heptanedioic acid, octanedioic acid, decanedioic acid,
undecanedioic acid, dodecanedioic acid, tridecanedioic acid,
and tetradecanedioic acid, have been identified in samples of
azelaic acid. These impurities occur in acid azelaic as pharma-
ceutical raw material. They originate from contamination of
the starting materials that are used for the preparation of
azelaic acid by synthesis (6,7) or by biotechnological methods
(8). The contamination of pharmaceutical raw materials has
been analysed during the research and development of active
substances to prevent the side effects that are associated with
their presence. Because of their toxic effects, the quantity of
contaminants is often minimised in raw material (9,10).
In the technology that is used to formulate specific dosages, a
particularly relevant impact is the reaction of the excipientswith the
active agent that is present in the dosage form (11). Excipients, such
as solvents, may interact with biologically active substances,
resulting in the formation of pharmacologically inactive or toxic
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products (12). Many authors have studied the hydrolysis reactions
that lead to decomposition of the active medicinal substance. One
of the problems that have been observed in pharmaceutical com-
positions during stability tests is the esterification of the carboxyl
groups in the presence of ethanol (13). In some cases, the interac-
tion is beneficial (14,15), but it typically leads to the formation of
undesirable substances in the final product (16).
The identification of new contaminants is critical in the
development of new medicinal products. The quantitative eval-
uation of dicarboxylic acids, including azelaic acid, may be per-
formed using high-performance liquid chromatography with
evaporative light-scattering detector (HPLC-ELSD) device
(17) and many gas chromatography (GC) devices. GC, with the
derivatisation of fatty acids to methyl esters, was used to deter-
mine the amount of azelaic acid in the oil paintings of old Flemish
master painters (18). A similar method was applied for the
evaluation of the composition of wall paintings (19). A modified
GC method using a mass spectrometer detector (GC-MS) was
applied to study the composition of Medieval and Renaissance
Florentine paintings that originally contained proteins and fatty
acids, including azelaic acid (20). GC-MS was also used to deter-
mine the content of azelaic acid in samples of air from the natural
environment (21,22). An interesting GC method to evaluate the
content of azelaic acid in the natural aquatic environment was
developed by Pusvaskiene et al. They used simultaneous
derivatisation and dispersive microextraction using immis-
cible liquids, acetone, and carbon tetrachloride, whereas
the ethylchloroformate was used as a reagent for
derivatisation (23). The GC method was intensively devel-
oped due to the difficulties of determining the method's
precision (24). The azelaic acid content in tobacco leaves
was determined by the modified GC-MS method using
methyl derivatives and by solid-phase microextraction
(25). In a complex mixture of carboxylic, dicarboxylic,
and amino acids, azelaic acid was assessed as a derivative
of isobutylchloroformate using GC coupled with positive
chemical ionization MS (GC-MS-PCI) (25).
The aim of this study was to identify impurities observed
during the stability tests of a new liposomal dosage form of
azelaic acid that is composed of phosphatidylcholine and a
mixture of ethyl alcohol and water using HPLC-ELSD, gas
chromatography–flame ionization detection (GC-FID), and
GC-MS methods.
MATERIALS AND METHODS
HPLC-ELSD Agilent Technologies 1200; methanol
(CHROMASOLV®, for HPLC, ≥99.9%, Sigma-Aldrich); water
(forHPLC, Sigma-Aldrich); chloroform (CHROMASOLV®Plus,
forHPLC,≥99.9%, contains 0.5–1.0%ethanol as stabilizer, Sigma-
Aldrich); 40% acetic acid (acetic acid solution for HPLC, Sigma-
Aldrich); column: Merck, Purospher Star RP, C18, 250×4 mm,
(5 μm); reference sample of azelaic acid (AA; Fluka, serial number
S38946); reference samples of identified impurities of azelaic acid,
undecanedioic acid (I1, Aldrich, serial number: 1365985) and
dodecanedioic acid (I2, Aldrich, serial number: MKBB0577);
0.20 μm syringe filters; 2 mL syringes; HPLC probes. The analysis
was performed in regard to the developed “in-house” new formu-
lation of azelaic acid. The formulation composition included:
azelaic acid, soya lecithin, ethyl alcohol, phosphate buffer pH 7.4,
and purified water.
HPLC-ELSD
For HPLC-ELSD analysis, we used a high-perfor-
mance liquid chromatograph (Agilent Technologies 1200)
and a Purospher Star RP, C18, 250×4 mm (5 μm) column
(Merck). Detection was performed by an ELSD detector.
The following mixtures were used for the mobile phase:
(A) methanol/water (5:95)+1.5% (v/v) acetic acid; (B)
water/methanol (5:95)+1.5% (v/v) acetic acid; and (C)
chloroform. The analysis time was 88 min; the gradient
information is gathered in Table I.
Detection was performed using ELSD. The flow rate of the
HPLCmobile phase was 1.0 mL/min, the column temperature was
30°C, and the injection volume was 50 μL. The temperature of the
nebulisation within the ELSD device was set at 40°C and the flow
rate of the inert gas—nitrogen—inside the detector was set at
1.6 mL/min. The following samples were tested: a liposomal for-
mulation of azelaic acid prepared without active substance (place-
bo, L), a liposomal formulation of azelaic acidwith active substance
(LA) and a reference sample of AA. The reference samples of the
identified impurities (I1 and I2) were prepared by dissolving them
in mobile phase B. During the evaluation of the assay method, the
solutions of the individual impurities (I1 and I2) and a mixture of
standards of known impurities (I1 and I2) were compared.
GC-FID
GC-FID was carried out using a gas chromatograph Agilent
7890GC System. Twomicrolitres of the sample was injected onto
the chromatographic column. Direct flow of the carrier gas (100:1
split) was provided with a flow rate of 0.8 mL/min. We used an
HP-5MS column (30 m×320 μm×0.25 μm). The isothermal tem-
perature of the chromatographic process was 70°C, whereas the
injector temperature was set at 270°C and the FID detector
temperature was maintained at 300°C. Helium carrier gas was
applied in the GC column and the mixture of a combustible
gas—hydrogen (35 mL/min)—and air (350 mL/min) was used in
the FID chamber. The active substance was processed as follows:
250 mg of the active substance was mixed with 5 mL of a 2-M
solution of chlorotrimethylsilane in methanol and then incubated
for 16 h at 80°C. The sample was filtered through a 0.45-μm teflon
syringe filter and injected after dilution with methanol for com-
parison with the reference solution. A sample of the final dosage
form of the azelaic acid was prepared by dissolving 1.6 g of the
Table I. Composition of Mobile Phase During the Assay
Time [min] Phase A (%) Phase B (%) Phase C (%)
0 90 10 0
3 90 10 0
10 55 45 0
40 15 85 0
60 0 100 0
63 0 100 0
65 0 80 20
71 0 80 20
72 0 100 0
76 0 100 0
81 90 10 0
88 90 10 0
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product in 10 mL of a 2-M solution of chlorotrimethylsilane in
methanol and was then incubated for 16 h at 80°C. The sample
was filtered through a 0.45-μm teflon syringe filter and injected
into the analytical system without dilution.
GC-MS
The qualitative analysis of the unidentified impurity
observed during the stability tests of liposomal formula-
tion of azelaic acid was performed using an HP 5890 II
gas chromatograph coupled with an HP 5971a mass
selective detector. An HP-5MS capillary column (30 m×
200 μm×0.25 μm, film—cross-linked 5% PH ME siloxane)
was used with helium, as the carrier gas at a constant flow
rate of 0.8 mL/min. The temperature of the column was
programmed from 70°C to 290°C at 25°C/min, after an
initial 1 min isothermal period and was maintained at the
final temperature for 10 min. The inlet was maintained at
290°C. One microlitre of the sample was injected in the
split mode (1:10) using a syringe. The mass spectrometer
was set at an ionising voltage of 70 eV with a mass range
of m/z 35–550. Sample preparation was carried out in the
same manner as the GC-FID testing.
RESULTS AND DISCUSSION
During the research and development of a new lipo-
somal formulation of azelaic acid (LA), we developed a
method for determining the contamination of AA using
HPLC with an ELSD detector. In preliminary studies of
the stability of the new medicinal product, an unidentified
impurity (NI) was observed with a retention time of ap-
proximately 31 min. According to the results of the sta-
bility tests, the impurity appeared after three months of
Table II. Unidentified Impurity with a Retention Time of Approxi-
mately 31 Min in the Liposomal Formulation of Azelaic Acid After









Long-term 25 60 0.11
Intermediate 30 60 0.76
Accelerated aging 40 75 3.33
Fig. 1. Comparison of HPLC-ELSD chromatograms of a mixture of azelaic acid
impurities I1 and I2 (a), liposomal formulation of azelaic acid LA (b), and samples
not containing azelaic acid with a composition identical to the composition of the
liposomal formulation L (c)
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testing the product in a long-term test, in an intermediate
test and in accelerated aging tests, as shown in Table II.
The abundance of the unidentified impurity NI with a
retention time of approximately 31 min exceeded 0.1%
of the calculated azelaic acid content. This 0.1% limit is
consistent with the “in-house” specification that was eval-
uated according to the ICH standards (26).
HPLC-ELSD Research
During the tests using the product sample, the place-
bo sample, and the azelaic acid sample, under the stan-
dard stress conditions of high temperature and/or
increased humidity, we showed that the peak with a re-
tention time of approximately 31 min appeared only in
the product sample (LA). The peak was not observed in
the mixture of excipients referred to as placebo (L). This
finding led to the conclusion that the unknown impurity is
formed via the reaction of azelaic acid with one of the
excipients of the liposomal formulation of azelaic acid.
The corresponding chromatograms are summarised in
Fig. 1. Chromatogram 1A shows a mixture of two identi-
fied impurities (I1 and I2) that are similar to the uniden-
tified impurities (NI). Chromatograms 1B and 1C are
from a liposomal formulation of azelaic acid with an ac-
tive ingredient (LA) and the azelaic acid liposomal for-
mulation without substance (L), respectively. The
formulations were stored under stress conditions of ele-
vated temperature and humidity, as indicated in Table I.
We followed several steps to identify the unknown
impurity. In the first stage of the study, we performed
the esterification reaction using AA and ethyl alcohol in
the presence of sulphuric acid. Consequently, in the sec-
ond stage we treated the liposomal formulation of azelaic
acid (LA) with sulphuric acid. The obtained reaction mix-
ture in the first case (AA) contained the ethyl monoester
and ethyl diester of azelaic acid—Fig. 2a. The recorded
retention times for respective peaks (Fig. 2a) enabled iden-
tification of AA and NI in the mixtures presented on the
Fig. 2b, c. In the second case, we obtained complex
Fig. 2. HPLC-ELSD chromatograms of the reaction products of AA with ethanol in the
presence of sulphuric acid (AA-Et) (a), the liposomal formulation of azelaic acid stored for
12 months (LA-Alt) (b), and the liposomal formulation of azelaic acid with ethanol in the
presence of sulphuric acid (LA-Et) (c)
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mixtures, which were further evaluated. The mixtures
were analysed using HPLC with an ELSD detector to
determine the impurities of azelaic acid. The resulting
chromatograms are shown in Fig. 2, along with a chro-
matogram of a sample of liposomal formulation of
azelaic acid that was stored for 12 months in ambient
conditions.
There are two main peaks in the chromatogram of the
sample reaction mixture of AA with ethyl alcohol in the
presence of sulphuric acid (Fig. 2a) that correspond to the
retention times of the peaks that were observed in the chro-
matogram of the test sample of the liposomal formulation of
azelaic acid stored through 12 months (Fig. 2b). Similar
maxima were observed in the case of samples of AA liposo-
mal formulation after addition of sulphuric acid as an esterifi-
cation accelerator (Fig. 2c). These peaks are the AA peak,
with a retention time of approximately 20.5 min and the
unidentified impurity (NI) peak, with a retention time of
approximately 31.5 min. Additionally, we observed another
peak at ca. 41.5 min in the chromatogram of the reaction
mixture; we attributed it to the diethyl derivative of AA. It
was not present in the liposomal formulation, due to the
low concentration of ethyl alcohol used in the production
process, compared with reaction mixture AA with ethyl
alcohol. Based on that observation, the unidentified impu-
rity of azelaic acid could be produced by the esterification
reaction and could be defined as a monoethyl ester of
azelaic acid, as shown in Fig. 3.
GC-FID Studies
In the next stage of the analysis, we performed meth-
od optimisation for the detection of AA of pollutants
using GC-FID. Prior to being applied to the column, the
samples were derivatised with a silylating reagent,
hexamethyldisilazane, according to the reaction scheme
shown in Fig. 4.
The chromatograms that were acquired during the
analysis of the following samples in the GC-FID device
are presented in Fig. 5: silylated sample of the reaction
mixture with ethanol and azelaic acid, designated AA-Et-
Sil (Fig. 5a); silylated products of the liposomal formula-
tion of azelaic acid prepared “ex tempore,” designated
LA-Sil-1 (Fig. 5b); and silylated products of the liposomal
formulation of azelaic acid stored for 12 months, desig-
nated LA-Sil-2 (Fig. 5c). The chromatogram of the AA-
Et-Sil (Fig. 5a) contains two peaks corresponding to the
retention times of the peaks that are observed in the
chromatogram of LA-Sil-2 (Fig. 5c), which is the test
sample of the liposomal formulation of azelaic acid that
was stored for 12 months. The retention time of 16.9 min
corresponds to AA, whereas the retention time of approx-
imately 16.6 min corresponds to the unidentified impurity
(NI). In the sample prepared ex tempore (Fig. 5b), we did










































Fig. 3. Scheme of azelaic acid esterification with ethanol
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the case of LA-Sil-1 and LA-Sil-2, the maxima observed
at 15.9 min and at around 18.4 min come from the com-
ponents of liposomal formulation (Fig. 5b, c)—we did not
observe them in the chromatogram of reaction mixture of
AA and ethyl alcohol (Fig. 5a).
During the analysis performed using HPLC-ELSD
and GC-FID measurement, we attempted to elucidate
the nature of the unidentified impurity by comparing the
position of the peak that was observed in the measure-
ment of the liposomal formulation of azelaic acid and the
peak of azelaic acid that was present in the reaction
mixture that was treated with ethyl alcohol in the pres-
ence of sulphuric acid.
GC-MS Studies
The third step of the identification of the compound
was performed by comparing the mass spectra obtained
during analysis of the samples, using a GC-MS device,
after derivatisation with a silylating reagent, as mentioned
above. The analysed samples comprised a mixture of ethyl
esters of azelaic acid, named AA-Et-Sil and samples of
the two series of liposomal formulations of azelaic acid:
one batch produced ex tempore, named LA-Sil-1 and one
batch that was stored for 12 months in ambient condi-
tions, named LA-Sil-2. As shown in Fig. 6, there are three
peaks in the chromatogram of the silylated mixture of
reacted azelaic acid (AA-Et-Sil): a peak with a retention
time of 7.77 min that was derived from the ethyl diester
of azelaic acid (DE-AA), a peak at a retention time of
8.03 min that was derived from the silylated ethyl mono-
ester of azelaic acid (ME-AA-Sil), and a peak with a
retention time of 8.28 min that was derived from silylated
azelaic acid (AA-Sil). Also, shown in Fig. 6 are the mass
spectra of the individual peaks.
The silylated peak of azelaic acid was identified by
comparison with known mass spectra that were obtained
from an available database. Confirmation of the position
of the peak identified as the silylated monoester of azelaic
acid was based on the work of Van der Berg, who studied
the mass spectra of dicarboxylic acids and showed that the
mass spectrum of the GC-MS peak with a retention time
of 8.03 min corresponds to the derivative of the silylated
ethyl monoester of azelaic acid. Comparison of the two
spectra confirms that the peak obtained experimentally in
our work is a silylated monoester derivative of azelaic
acid. Additionally, comparison of the mass spectra of the
peak with a retention time of 8.0 min that is derived from
a mixture of esters of azelaic acid (AA-Et-Sil) and the
test sample of the liposomal formulation of azelaic acid
that was stored for 12 months (LA-Et-Sil-2) confirms that
the two peaks are derived from the same compound, in
accordance with the data shown in Fig. 7.
Additional verification of the chromatograms and
confirmation of accurate identification of the assessed im-
purity as the ethyl monoester of azelaic acid was carried
out by comparing the GC-MS chromatograms of the fol-
lowing samples: the liposomal formulation of azelaic acid
Fig. 5. GC-FID chromatograms: a silylated sample of the reaction mixture with ethanol and
azelaic acid (AA-Et-Sil); b silylated products of the liposomal formulation of azelaic acid
prepared “ex tempore” (LA-Sil-1); and c silylated products of the liposomal formulation of
azelaic acid stored for 12 months (LA-Sil-2)
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prepared ex tempore (LA-Et-Sil-1) and the liposomal for-
mulation of azelaic acid that was stored for 12 months
(LA-Et-Sil-2), as shown in Fig. 8. The chromatogram of
the tested sample of the liposomal formulation of azelaic
acid that was stored for 12 months shows a distinct peak
originating from the ethyl monoester of azelaic acid, with
a retention time of approximately 8.00 min. A similar but
less distinct peak is observed in the chromatogram of the
sample of the liposomal formulation of azelaic acid, pre-
pared ex tempore; the visible small peak was derived from
the ethyl monoester of azelaic acid and has a retention
time of 8.02 min. The peak at ca. 7.77 min may be
attributed to the diethyl derivative of azelaic acid,
however detailed analysis needs further research, with
extended evaluation of GC-MS spectra.
During the assessments, we observed some peaks in the
HPLC-ELSD chromatograms which may be attributed to the
diethyl ester of AA. Actually, in the reaction of AA with
ethanol, there should be two esters formed: ethyl ester and
diethyl ester of AA, as it is presented on the Fig. 3. We
identify the peak at 41.4 min as the possible diethyl ester of
AA—Fig. 2a (DE); however, the investigation of this deriva-
tive of AA will be performed in another study. The applied
silylation reaction, which enables derivatization, occurs in the
presence of available hydroxyl groups, which are blocked in
the dietyl ester of AA, so further research will be planned.
Fig. 6. GC chromatograms obtained from the measurements of the silylated products of the reaction of
azelaic acid with ethanol in the presence of sulphuric acid (AA-Et-Sil) with the corresponding mass spectra
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CONCLUSIONS
During our analytical tests, we identified a previously
unknown impurity of a liposomal preparation of azelaic
acid that appeared in the liposomal formulation of azelaic
acid during preliminary stability studies. The results led to
the conclusion that the impurity was caused by the reac-
tion of azelaic acid with one of the excipients that was
applied in the product, i.e., with ethanol. The impurity was
finally identified as an ethyl monoester of azelaic acid. The
identification procedure of this compound was carried out in a
series of experiments comparing the chromatograms that
were obtained via the following chromatographic methods:
HPLC-ELSD, GC-FID, and GC-MS. In our study, we
synthesized an in-house ethyl monoester of azelaic acid
by performing the esterification reaction of azelaic acid.
The similarity of the retention time of the obtained com-
pound to that of an unidentified peak in the chromato-
gram of the sample of the liposomal formulation of
azelaic acid was confirmed by two independent methods
of chromatographic separation: HPLC-ELSD and GC-
FID. The final identification of the compound was carried
out by GC with MS. The final product and the mixture of
esters had identical mass spectra. Furthermore, the mass
Fig. 7. Mass spectra of two peaks with a retention time of approximately 8.0 min: AA-Et-Sil mass spectrum
of the silylated derivative of the monoester of azelaic acid that was obtained on the silylated products of the
reaction of azelaic acid with ethanol in the presence of sulphuric acid; LA-Et-Sil-2 silylated products of the
reaction of the liposomal formulation of azelaic acid with ethanol in the presence of sulphuric acid after
12 months of storage
118 Han et al.
spectrum present in the literature confirms that the gen-
erated impurity of azelaic acid is the ethyl monoester of
azelaic acid. Some of the peaks within the analyzed spec-
tra suggest the presence of diethyl ester of azelaic acid;
however, we did not observe diethyl ester of azelaic acid
within the liposomal preparations.
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